Genomma Lab’s Offer to Acquire Prestige Brands

April 26, 2012
Executive Summary
At $16.60 per share, Genomma’s offer values Prestige’s equity at $856 million, which represents a:

1. 23% premium to the 1 day prior to announcement compared to a median 1-day premium paid in the sector over the last 10 years of 21%.
2. 33% premium to the 30 days prior to announcement compared to a median premium paid of 25%.
3. 9.3x EBITDA multiple, consistent with precedent transactions in the sector over the last 10 years, including Chattem (an outlier), which have a median EBITDA multiple of 9.1x.

Genomma’s offer multiple is a 26% premium to the 7.4x multiple Prestige recently paid for the GlaxoSmithKline ("GSK") assets:

1. The GSK assets now generate ~40% of Prestige’s pro forma EBITDA.
2. The value of the GSK assets was extensively evaluated and determined by Prestige as part of a widely-auctioned sale process.

Therefore, when keeping the value of the GSK assets static, the Genomma offer implies a 10.7x multiple on Prestige’s legacy business:

- A multiple of 10.7x is significantly higher than Prestige has ever been valued.
- Multiple represents a 37% premium to Prestige’s 3-year average EBITDA multiple of 7.8x.
## Deal Certainty — Conditions Have Been Largely Removed

### Shareholder Approval

- Received Genomma shareholder approval on March 29, 2012 for the proposed transaction
- Shareholders also delegated authority to the Board to finalize the negotiations

### Other Conditions

- Transaction requires only customary financial and regulatory closing conditions
- No unique closing conditions are required

- Once Prestige opens the door for Genomma to conduct due diligence, Genomma and its team of advisors are ready to move quickly to complete their diligence
Prestige Refuses to Engage Despite Genomma Addressing Its Concerns Regarding Genomma’s Proposal

- Prestige management continues to refuse a dialogue in spite of clear guidance that conditionalities have largely been removed and potential price flexibility exists subject to due diligence
  
  - On April 5, 2012, Genomma’s financial advisors reached out to Prestige’s financial advisors in an effort to initiate a friendly dialogue and implement a constructive process to negotiate a transaction with Prestige
  
  - On the same date, Genomma’s CEO directly spoke to Prestige’s CEO to convey the same message
  
  - Both efforts were met with the unambiguous message that Prestige’s management and Board of Directors have no intention to consider a transaction with Genomma at this point

- The refusal by Prestige to engage forces Genomma to pursue a transaction directly with Prestige shareholders

- Genomma has a desire to engage in a meaningful dialogue and conduct due diligence

- In the meantime, Prestige shareholders should closely scrutinize Prestige’s future value proposition as a standalone entity, as well as certain claims made by Prestige management designed to discredit Genomma’s offer

Sources: Genomma filings.
Lack of Organic Growth

- **Prestige’s results are largely absent of any organic growth since its initial public offering ("IPO"), including the Company’s most recent reported periods**
  - In FY 2011, the first full year under the current management team, Prestige had organic growth of 1.7%
  - For the first nine months of FY 2012, Prestige’s organic growth turned negative (-0.1%)

- **Recently, Prestige management suggested that this trend is not about to change**
  - “I’m not sure that I would model an ongoing 3% organic growth rate in this economic environment.”
    — Matt Mannelly, CEO of Prestige Brands (Q3 2012 earnings call; February 9, 2012)

- **Wall Street analysts also share a pessimistic view concerning Prestige’s ability to grow organically**
  - “We anticipate relatively flat organic sales growth, with higher sales of core OTC healthcare brands offset by lower sales of non-core OTC and household cleaning brands.”
    — Jon Andersen, William Blair (February 9, 2012)

- **Prestige’s lack of organic growth, both historically and more recently under new management, demonstrates the key limitation of the business model**
  - The inability to reinvigorate and grow brands once they have been acquired

Sources: Prestige filings, Prestige earnings call transcripts and Wall Street research.
Prestige Brands — A Roll-Up Strategy and Business Model at Its Core

• Prestige management has been successful in acquiring brands and integrating them into the business

• Acquisitions have, however, been Prestige’s only source of growth and value creation in the 2+ years since the current management team joined

  — In fact, aside from Prestige’s stock price movements between the announcement and closing dates of Prestige’s three most recent acquisitions (1), its stock price performance was negative (-2.6%) (2)

• With a fully-levered balance sheet following the GSK brands acquisition, Prestige is significantly constrained from pursuing any meaningful M&A activity

• In its March 22, 2012 Investor Presentation, Prestige management suggested that it would take up to 24 months to regain financial flexibility to continue its acquisition strategy

• In the meantime, without any organic growth, no evidence exists to reassure shareholders that any growth or value creation can actually occur

Sources: Prestige filings, Capital IQ and Wall Street research.

1) Prestige’s three most recent acquisitions include Dramamine, Blacksmith Brands and GSK’s North American OTC brands.

2) Represents the cumulative price performance from September 2, 2009 (appointment of current management team) through February 17, 2012, excluding price performance between the announcement and the close of the Dramamine, Blacksmith Brands and GSK North American OTC brands acquisitions.
Prestige Faces Significant Challenges as a Standalone Company

- **Continuing pressure on Prestige’s household products business**
  - Household products revenue declined 6.9% in the first nine months of FY 2012 primarily due to lower sales of Comet
  - Management has announced a plan to “stabilize” its household products business by launching new products in an attempt to mitigate the declining revenue
  - The household products sector is very competitive and price sensitive, with the main competitors all being large companies with significant sales and marketing clout

- **The potential reemergence of J&J’s Children’s business**
  - J&J pulled its Children’s Tylenol product from the market in April 2010 due to manufacturing problems
  - Prestige’s Pediaicare / Little brands clearly benefited from this one-time occurrence, and the specific growth Prestige experienced with these brands in this period is not sustainable

- **Prestige has acknowledged that its advertising and promotion ("A&P") spend needs to meaningfully increase in the coming years**
  - This will put direct pressure on Prestige’s margins in an environment that remains intensely competitive
  - Combined with the fact that there can be no further acquisitions in the foreseeable future, this will put further pressure on both the top and bottom line

- **Prestige increasingly competes with OTC / consumer products companies of massive scale**
  - Prestige, with a market cap of less than $700 million, is subject to competition from large, multi-national corporations such as Procter & Gamble, which has a market cap of ~$180 billion
  - Large-cap consumer packaged goods (“CPG”) and pharma competitors possess international platforms and marketing and manufacturing capabilities far beyond that of Prestige

Sources: Prestige filings, Capital IQ and Wall Street research.
Genomma is Better Positioned to Reinvigorate Prestige’s Growth in Ways Unattainable as a Standalone Company

- **Genomma will make the type of investment required to create sustainable organic growth**
  - Genomma has internally developed most of its more than 80 brands and has taken them to the number 1 or number 2 market share positions
  - A proven track record of reinvigorating brands through the development of line extensions, advanced formulas and innovative packaging
  - Unique in-house marketing capability of optimally creating and customizing brand awareness

- **Genomma has the ability to regionalize both Prestige and Genomma’s leading brands**
  - Unique opportunity to expand Prestige’s brand portfolio in Mexico and the 14 other Latin American markets in which Genomma operates
  - Genomma would gain shelf space and a footprint in the U.S. and Canada for several of its own key brands

- **Prestige’s product portfolio is an excellent complement to Genomma’s product portfolio**
  - Creates a comprehensive product offering across the top OTC and personal care categories in the U.S., Canada and Latin America
Shareholders Should Carefully Scrutinize Certain Claims Made by Prestige

<table>
<thead>
<tr>
<th>Prestige Claims</th>
<th>Genomma Perspective</th>
</tr>
</thead>
</table>
| • Genomma’s timing is opportunistic and intercepted a rising stock price | • Opportunistic implies bidding at a low point  
  – Meanwhile, Prestige shares climbed 43% following the announcement of the GSK transaction, setting a new 52-week high  
  – In fact, Prestige was at a 5-year high |
| • Value of Prestige’s tax asset was not reflected in Genomma’s offer | • Prestige was trading at an 8.6x EBITDA multiple, significantly higher than its 3-year average of 7.8x and 2-year average of 8.0x  
  • Momentum had subsided at the time of the offer  
  – Prestige actually underperformed the S&P 500 between the GSK brands closing and Genomma’s offer (1) |
| | • The value was reflected in Prestige’s share price  
  • The rise in Prestige’s share price represented an increase of $209 million in equity value  
  – 55% more than the $135 million tax asset Prestige reported as part of the GSK acquisition  
  • The market was fully aware of the value of the tax asset as Prestige had clearly highlighted it and quantified it in its press release, 8-K filing and investor presentation |

Sources: Prestige filings, Prestige press releases, Capital IQ and Wall Street research.
(1) For the period February 1, 2012 through February 17, 2012, the last trading day prior to Genomma’s proposal.
Shareholders Should Carefully Scrutinize Certain Claims Made by Prestige

**Prestige Claims**

- Average premium paid in precedent M&A transactions is 39%
- Sanofi’s acquisition of Chattem for 13.6x EBITDA represents the comparable EBITDA multiple paid in precedent transactions

**Genomma Perspective**

- Prestige’s analysis goes back 20 years
- It is customary to measure transactions across a more current period, excluding outlier periods that skew the data, such as during the dot.com bubble
- Looking at the data over the last 10 years:
  - Average 1-day premium paid of 29% \(^{(1)}\)
  - Average 30-day premium paid of 33% \(^{(2)}\)
- Prestige only highlights 1 transaction in its precedent(s) analysis
  - It is customary to use a robust data set, not 1 data point
- For several important reasons, including growth, scale and low leverage, Chattem consistently traded on average at a 48% higher multiple than that of Prestige
- Using a more customary approach, comparable transactions in the sector over the last 10 years (including Chattem):
  - The median EBITDA multiple is 9.1x

Sources: Prestige filings and investor presentation; Wall Street research; Dealogic; and Capital IQ.
Notes: The terms “EBITDA” and “multiple” refer to Last 12 Months EBITDA. EBITDA multiple refers to Enterprise Value / Last 12 Months EBITDA.
1) Includes only completed, all-cash, public transactions for the consumer and retail industry for the period April 5, 2002 through April 5, 2012, where premium data is available. Sample limited to change of control transactions (>50% stake acquired), transactions over $100 million transaction value and transactions involving US targets.
2) Includes only completed, all-cash public transactions across all industries for the period April 5, 2002 through April 5, 2012, where premium data is available. Sample limited to change of control transactions (>50% stake acquired), transactions over $100 million transaction value and transactions involving US targets.
Shareholders Should Carefully Scrutinize Certain Claims Made by Prestige

- Peer group has radically changed

<table>
<thead>
<tr>
<th>10-K Reported Peers</th>
<th>Investor Presentation Peers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helen of Troy</td>
<td>Helen of Troy</td>
</tr>
<tr>
<td>WD-40</td>
<td>WD-40</td>
</tr>
<tr>
<td>Elizabeth Arden</td>
<td>Church &amp; Dwight</td>
</tr>
<tr>
<td>The Hain Celestial Group</td>
<td>The Clorox Company</td>
</tr>
<tr>
<td>Inter Parfums</td>
<td>Colgate-Palmolive</td>
</tr>
<tr>
<td>Lifetime Brands</td>
<td>Energizer</td>
</tr>
<tr>
<td>Maidenform</td>
<td>Jarden</td>
</tr>
<tr>
<td>Smart Balance</td>
<td>Newell Rubbermaid</td>
</tr>
<tr>
<td>Zep</td>
<td>Perrigo</td>
</tr>
<tr>
<td></td>
<td>Procter &amp; Gamble</td>
</tr>
<tr>
<td></td>
<td>Reckitt Benckiser</td>
</tr>
<tr>
<td></td>
<td>Schiff</td>
</tr>
<tr>
<td></td>
<td>Tupperware</td>
</tr>
</tbody>
</table>

Sources: Prestige filings, Prestige investor presentation and Capital IQ.
Notes: The terms “EBITDA” and “multiple” refer to Last 12 Months EBITDA. EBITDA multiple refers to Enterprise Value / Last 12 Months EBITDA.
1) Market values as of February 17, 2012.

- The median market value of the new peers is $5.6 billion vs. $694 million for Prestige (1)

- Investor presentation peers include P&G, Colgate and Reckitt Benckiser, who have equity values of $179 billion, $45 billion and $41 billion, respectively
  - These companies far surpass Prestige in terms of scale, brand recognition and international capabilities

- Conveniently, this group trades at an EBITDA multiple ~2 turns higher than the long-established historical peer group
Prestige Share Price Performance
The Company’s Organic Growth Has Been Flat Since 2010

• Prestige exhibited less than 2% organic growth in FY 2011
  – The revenue contribution from the Dramamine and Blacksmith Brands acquisitions was almost exactly equal to Prestige’s total year-over-year revenue increase
  – Prestige’s existing portfolio barely grew from FY 2010 to FY 2011

• Prestige’s organic growth actually declined in the 9 months ending December 31, 2011, after adjusting for acquisitions
  – For the current fiscal year to date, the Company’s revenue has declined by $1.7 million before acquisitions

Sources: Prestige filings, Wall Street research and Capital IQ.
Prestige Has Historically Traded at a Significant Discount to Its Peers
Historical EV / LTM EBITDA multiples

- **Prestige has consistently been valued at a significantly lower multiple than its peers**
  - Prestige has traded at 8.0x EBITDA over the last 2 years vs. 10.0x for its peers

- **Chattem traded at an average multiple of 11.8x EBITDA during the 2 years prior to its acquisition by Sanofi**
  - ~4 turns (48%) higher than Prestige’s 2-year average for the last 2 years
  - Chattem and Prestige’s peers are valued at higher multiples due to
    - Superior growth
    - Superior scale
    - Lower leverage

### Historical Multiples

<table>
<thead>
<tr>
<th></th>
<th>2-Year Trailing Average Prior to Offer</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-K Reported Peers</td>
<td>10.0x</td>
</tr>
<tr>
<td>Chattem</td>
<td>11.8x</td>
</tr>
<tr>
<td>Prestige</td>
<td>8.0x</td>
</tr>
<tr>
<td>Discount to Peers</td>
<td>(19.3%)</td>
</tr>
<tr>
<td>Discount to Chattem</td>
<td>(31.9%)</td>
</tr>
</tbody>
</table>

Source: Capital IQ for the period December 20, 2007 through February 17, 2012.

Notes: The terms “EBITDA” and “multiple” refer to Last 12 Months EBITDA. EBITDA multiple refers to Enterprise Value / Last 12 Months EBITDA.

1) 10-K Reported Peers include Elizabeth Arden, Hain Celestial, Helen of Troy, Inter Parfums, Lifetime Brands, Maidenform Brands, Smart Balance, WD-40 and Zep.
Management Guidance

“I think we all know, in the OTC market, the OTC market is a steady and slow market. And if you look at OTC in general the last two to three years, it's a plus 1% or 2% market overall across all categories. So it's not like these brands or any of the other brands that we've purchased have had double-digit growth rates. And I wouldn't say that would be true with this portfolio just like it wasn't with the past ones.”

— Matt Mannelly, CEO; Prestige Brands Holdings (December 20, 2011)

Wall Street Perspective

“...we believe the stock already incorporates much of this upside, having appreciated over 40% since announcing the transaction on December 20. Thus, we view the shares as fairly valued at 10.6x our revised fiscal 2013 EPS estimate, particularly given the lack of sustainable consolidated organic top-line growth and a now-levered balance sheet, with a leverage ratio of over 5x.”

— Joseph Altobello, CFA; Oppenheimer & Co. (February 9, 2012)

“Shares currently trade at 11.5 times our calendar 2012 EPS estimate and we view risk/reward profile as balanced.”

— Jon Andersen, CFA; William Blair & Company (February 9, 2012)
The Value of the GSK Deal, Including the Tax Asset, Was Reflected in Prestige’s Stock Price Prior to Genomma’s Proposal

- Value of GSK deal had accreted into Prestige’s stock price
  - Between the announcement and close of the GSK deal, Prestige appreciated 43%, representing an increase of $209 million in equity value
  - This is 55% more than the $135 million tax benefit Prestige reported

- No momentum post-GSK transaction
  - Following the close of the GSK brands acquisition, Prestige underperformed the S&P 500

Sources: Prestige filings, investor presentation, website and press releases; and Capital IQ.
Price Rationale
Genomma’s Proposal Represents a Compelling Value for Prestige Shareholders

- **Consideration**: $16.60 per share (100% cash)

- **Premium**: 23% premium to the unaffected stock price of $13.50 on February 17, 2012
  - 33% premium to the 30 days prior to announcement

- **Valuation**: 9.3x LTM EBITDA

- **Prestige Shareholder Proposal**: Genomma has nominated a slate of five directors for Prestige’s Board

- **Genomma Shareholder Approval**: Received shareholder approval on March 29, 2012 for the proposed transaction
  - Shareholders also delegated authority to the Board to finalize the negotiations
Genomma’s Offer Premium is Consistent with Similar Completed Transactions Over the Last 10 Years

Source: Dealogic as of April 5, 2012.
Note: Includes the median percentage of only completed, all-cash, public transactions for the period April 5, 2002 through April 5, 2012, where premium data is available. Sample limited to change of control transactions (>50% stake acquired), transactions over $100 million transaction value and transactions involving US targets.
Compelling Value Post GSK Acquisition

Genomma Offer Multiples Analysis

<table>
<thead>
<tr>
<th>Multiples</th>
<th>Value ($ Millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EV/LTM EBITDA (x)</td>
<td></td>
</tr>
<tr>
<td>GSK Brands NA Transaction Value</td>
<td>7.4x</td>
</tr>
<tr>
<td>Genomma Offer for Prestige</td>
<td>9.3x</td>
</tr>
<tr>
<td>Implied Genomma Offer for Legacy Prestige (excl. GSK)</td>
<td>10.7x</td>
</tr>
</tbody>
</table>

Sources: Prestige filings, investor presentation, website and press releases; Genomma filings; Wall Street research; and Capital IQ.

1) Includes approximately 50.4 million basic common outstanding shares, 0.3 million restricted stock / restricted stock units and 1.8 million options at a weighted average strike price of $8.48 per share; per Prestige’s latest 10-Q for the period ended December 31, 2011.
2) Per Prestige press release dated December 20, 2011.
3) Based on $215 million pro forma combined EBITDA cited in Prestige investor presentation (dated March 22, 2012) less $89.2 million of GSK brands EBITDA (implied from 6x net purchase multiple cited in Prestige press release dated December 20, 2011).
Over the Last 2 Years, the Median Multiple Prestige has Paid for Its Acquisitions is 7.4x

The Prestige acquisitions account for ~60% of the Company’s EBITDA and have not generated any meaningful organic growth, yet the Genomma offer is a significant premium to those valuations.

Sources: Company filings, Wall Street research and Capital IQ.
Notes: Line indicates group median excluding Prestige / Genomma transaction. Percentages indicate premiums to the group median.
**Precedent Transactions and Peer Group Trading Levels**

Offer is in line with precedents and peers, and represents a significant premium to any value that Prestige has recently achieved or at which it has acquired.

<table>
<thead>
<tr>
<th></th>
<th>TEV / LTM EBITDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestige Prior</td>
<td>7.4x</td>
</tr>
<tr>
<td>Transactions</td>
<td></td>
</tr>
<tr>
<td>Precedent Transactions</td>
<td>9.1x</td>
</tr>
<tr>
<td>10-K Reported Peers</td>
<td>10.5x</td>
</tr>
<tr>
<td>Genomma Offer for</td>
<td>9.3x</td>
</tr>
<tr>
<td>Prestige</td>
<td></td>
</tr>
<tr>
<td>Genomma Offer for</td>
<td>10.7x</td>
</tr>
<tr>
<td>Legacy Prestige</td>
<td></td>
</tr>
</tbody>
</table>

Sources: Company filings, Wall Street research and Capital IQ. All pricing as of February 17, 2012.

Note: Each bar represents group median.

(1) Prestige prior transactions include: Dramamine/Prestige; GSK NA OTC brands/Prestige; and Blacksmith Brands/Prestige.

(2) Precedents include Del Pharma/CHD, Chattem/Sanofi, Del Labs/Kelso, PBM Nutritional/Perrigo, NBTY/Carlyle, Dramamine/Prestige, GSK NA OTC/Prestige, Blacksmith/Prestige.

(3) 10-K Reported Peers include Elizabeth Arden, Hain Celestial, Helen of Troy, Inter Parfums, Lifetime Brands, Maidenform Brands, Smart Balance, WD-40, and Zep.
Conclusions
**Pro-Shareholder Governance Proposals**

<table>
<thead>
<tr>
<th>Genomma’s Proposals</th>
<th>Rationale for Proposals</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Fill the five Prestige directorships up for election with Genomma’s nominees</td>
<td>• Elect highly-qualified, independent directors to the Board</td>
</tr>
<tr>
<td>• Repeal any by-law amendments adopted by Prestige’s Board of Directors without shareholder approval</td>
<td>• Ensure that the current Prestige Board does not pre-emptively disenfranchise shareholders</td>
</tr>
<tr>
<td>• Accept the offer extended by Genomma to acquire all outstanding shares of Prestige at the price of $16.60 per share in cash</td>
<td>• Maximize shareholder value</td>
</tr>
</tbody>
</table>
Prestige’s Roll-up Strategy Has Successfully Run Its Course

• **Genomma is offering a significant premium at a high point, not a low point**
  – The offer fully incorporates the value of the recently acquired GSK assets, including the tax asset, and a significant premium on top of that

• **Genomma’s fully-financed proposal and shareholder approval creates deal certainty**

• **Prestige faces significant challenges as a standalone company**
  – All-cash offer transfers 100% of risk from Prestige shareholders to Genomma

• **Genomma is best positioned to organically grow Prestige’s brands successfully**
  – The comprehensive product offering and expanded international presence will provide substantial upside potential for organic growth for both product portfolios
  – Genomma can effectively apply its expertise in in-house marketing and R&D to significantly improve Prestige’s operations